低能量体外冲击波治疗缺血性心脏病

缺血性心脏病是导致死亡的主要原因。低能量体外冲击波治疗可以通过增加血管内皮生长因子的mRNA的表达、增加心肌有效灌注和改善左室重塑,从而改善缺血性心脏病患者的症状,减少硝酸甘油的服用,达到治疗缺血性心脏病的目的。     

U波异常有助诊断缺血性心脏病—冠脉造影与心电图对照

目的 探讨U波异常在诊断缺血性心脏病中的价值。方法 选择临床拟为冠心病的男性患者52例，排除电解质紊乱，应用常规心电图、运动负荷心电图及冠脉造影，分析ST段缺血性改变、U波异常在诊断缺血性心脏病中的敏感性和特异性。结果 52例临床拟诊冠心病患者，冠脉造影阳性者38例。冠脉造影阳性者中，常规心电图ST段呈缺血性改变者16例，U波异常者8例，其诊断缺血性心脏病的灵敏度分别为42．11％、21．11％(16/38、8/38)；运动试验阳性者26例，运动诱发U波异常者15例，其诊断缺血性心脏病的灵敏度分别为68．42％、39．47％(26/38、15／38)。冠脉造影阴性者(n＝14)中，常规心电图ST段无缺血性改变6例，U波正常13例，特异度分别为42．86％、92．86％(6／14、13／14)5运动负荷时，结果 阴性9例，U波正常14例，特异度分别为64．29％、100％(9／14、14／14)。运动负荷时尚见2例单独U波异常，其冠脉造影证实有病理性狭窄。结论 U波异常在诊断缺血性心脏病中敏感性虽不如ST段下移的高，但U波异常的特异性高，尤其是运动诱发的U波异常更具诊断价值；缺血性U波异常有助诊断冠心病。     

体外心脏震波治疗缺血性心脏病进展——一种新的治疗性血管新生法

介绍心脏震波治疗技术在治疗终末期冠状动脉粥样硬化性心脏病的历史中运用的历史与现状以及进展,对其适应证、方法、疗效评估等方面进行综述。     

肥大细胞与缺血性心脏病

心脏中存在肥大细胞。在心肌缺血状态下,心脏肥大细胞密度增多并处于功能活跃状态。肥大细胞通过释放细胞因子、炎症介质、蛋白酶等内容物,参与动脉粥样硬化、心肌梗死、充血性心力衰竭等疾病的病理过程。现就当前对肥大细胞与缺血性心脏病关系的相关研究进行综述。     

微小核糖核酸在缺血性心脏病中的研究进展

微小核糖核酸是一类参与生长发育、肿瘤发生、器官形成等生物学过程的重要调控因子。近期研究发现,微小核糖核酸与缺血性心脏病有重要关联,调节缺血或梗死后心肌纤维化、心律失常发生、血管成形术后再狭窄、新生血管形成以及心肌再生,影响心脏的机械重构、电重构及血管重构。以上发现使得微小核糖核酸有望成为缺血性心脏病新的治疗靶点。     

细胞因子治疗缺血性心脏病最新进展

缺血性心脏病是严重危害人类健康的常见疾病。细胞因子可通过祖细胞的动员归巢或激活其他血管生成因子以促进血管新生,从而具有治疗缺血性心脏病潜能。近年来越来越多的细胞因子进行了相关的实验研究和临床试验,现就其最新进展作一综述。     

再生医学在缺血性心脏疾病治疗中的应用

再生医学的发展为终末缺血性心脏病的治疗提供了新思路,有很大的临床应用前景,主要分三个阶段。现主要就第一阶段的研究现状从基础和临床两个方面介绍。     

Mesenchymal Stem Cell (MSCs) Therapy for Ischemic Heart Disease: A Promising Frontier

Although tremendous progress has been made in conventional treatment for ischemic heart disease, it still remains a major cause of death and disability. Cell-based therapeutics holds an exciting frontier of research for complete cardiac recuperation. The capacity of diverse stem and progenitor cells to stimulate cardiac renewal has been analysed, with promising results in both pre-clinical and clinical trials. Mesenchymal stem cells have been ascertained to have regenerative ability via a variety of mechanisms, including differentiation from the mesoderm lineage, immunomodulatory properties, and paracrine effects. Also, their availability, maintenance, and ability to replenish endogenous stem cell niches have rendered them suitable for front-line research. This review schemes to outline the use of mesenchymal stem cell therapeutics for ischemic heart disease, their characteristics, the potent mechanisms of mesenchymal stem cell-based heart regeneration, and highlight preclinical data. Additionally, we discuss the results of the clinical trials to date as well as ongoing clinical trials on ischemic heart disease.     

Hypertriglyceridemia—Acute Pancreatitis—Ischemic Heart Disease

ABSTRACT Hyperlipoproteinemia type V, with serum triglyceride concentrations of about 20 mmol/1, was detected in a pair of monozygotic, 40-year-old twin brothers. One of them had had recurrent attacks of pancreatitis, the other not. The endocrine and exocrine pancreatic functions were apparently normal, supporting that the pancreatitis was secondary to the hypertriglyceridemia. After successful lipid-lowering therapy the attacks of abdominal pain disappeared and remained absent during a 13-year follow-up period. The other twin died of ischemic heart disease nine years after the discovery of his lipid abnormality. The reduction of his lipid levels had been much less successful. His average “atherogenic index” (the ratio of cholesterol in low density to that in high density lipoproteins) was normal but increased to a very high value if cholesterol in very low density lipoproteins was also included together with the low density ones in the numerator. Lipoprotein particles modified in composition may have contributed to an increased uptake through a scavenger pathway and promoted atherosclerosis.     

Exercise as a Therapeutic Intervention in Patients with Stable Ischemic Heart Disease: An Underfilled Prescription

Treatment for stable ischemic heart disease may include guideline-directed pharmacologic therapy, coronary revascularization, and lifestyle and behavioral changes, including structured exercise. Of these, regular exercise is arguably one of the most cost-effective yet underused interventions. Most patients with stable ischemic heart disease are eligible for secondary prevention programs, which should include exercise training regimens, but participation in such programs remains suboptimal. This review emphasizes the importance of education for both patients and providers to enhance participation in lifestyle physical activity, structured exercise, or both.     

微血管病变与缺血性心脏病

冠状动脉微血管在心肌的血供中起着重要作用,冠状动脉微循环对冠心病的发生、发展、疗效及预后具有重要影响而备受人们重视。目前冠状动脉微血管病变主要分为X综合征和冠脉内慢血流现象,二者都与缺血性心脏病存在着密切的关系,但发病机制有所不同。X综合征主要是冠状动脉微血管痉挛所致,而冠脉内慢血流现象传统上被认为与微血管功能失调有关。此外慢血流现象可能是缺血性心脏病的一种新的发病机制,它可能代表了动脉粥样硬化和内皮功能失调的早期阶段。并且二者在治疗上有所不同。     

Personality and Mortality from Ischemic Heart Disease and Stroke

Background. The role of personality in the causation of circulatory diseases has been controversial. Methods. From June through August 1990, 41,442 residents of Miyagi Prefecture in northern Japan completed the Japanese version of the short-form Eysenck Personality Questionnaire-Revised and another questionnaire on various health habits. During 11 years of follow-up until March 31, 2001, we identified 90 deaths from ischemic heart disease (IHD) and 131 deaths from stroke. We used Cox regression to estimate the relative risk of IHD and stroke according to the three levels of four personality subscales (extraversion, neuroticism, psychoticism, and lie), with adjustment for sex, age, and other potentially confounding variables. Results. Multivariate relative risks of IHD for the highest verses the lowest level of personality subscales were 0.7 for extraversion, 1.1 for neuroticism, 1.3 for psychoticism, and 0.8 for lie. Multivariate relative risks of stroke for the highest verses the lowest level of personality subscales were 1.0 for extraversion, 0.9 for neuroticism, 1.2 for psychoticism, and 1.2 for lie. Conclusions. This prospective study does not support the hypothesis that personality is a risk factor for mortality from IHD and stroke.     

氯吡格雷在缺血性心脏病中的应用

缺血性心脏病是威胁人类生命的主要病因 ,氯吡格雷可显著减少心脏不良事件。